Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
CAMBRIDGE, Mass., May 01, 2018 -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), today announced that it will release its financial results for the first quarter ended March 31, 2018 and provide a corporate update before the U.S. financial markets open on Tuesday, May 8, 2018.
Management will host a conference call on that date at 8:00 a.m. ET to discuss these results and provide an update on the company. To access the call, please dial (877) 224-9084 (domestic) or (720) 545-0022 (international) prior to the scheduled conference call time and provide the access code 7665388. A live webcast of the call will be available on the "Investors" section of the company's website, www.momentapharma.com. An archived version of the webcast will be posted on the Momenta website approximately two hours after the call.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Contact:
Sarah Carmody
Momenta Pharmaceuticals
1-617-395-5189
[email protected]
